But at the time the company was considering the trial, Peter Johannsen, international medical vice president of Novo Nordisk, told Being Patient that blood biomarkers werent developed to the extent where they could be used to screen for people at-risk while cognitively healthy and would require PET scans or lumbar punctures, making a large study difficult to run
Most adult patients have lost 15% of their body weight or an average of 35 pounds while taking semaglutide
This concern would always be there with questions of patient noncompliance, but this study design in particular lends itself to this type of error
The cluster of India, China and Mexico show high differences in prevalence but contain a high level of absolute number of potential patients indicating their important size, coupled with high OOP exposure
Imagine someone who lost weight quickly on Ozempic: in the short term, they might notice more shedding, feel anxious about hair density, and tighten their diet even furtherunintentionally compounding stress
2014;129:S102S138